Home » Newsletters » BioWorld Science

BioWorld Science

May 21, 2007

View Archived Issues

Genzyme reports on active first quarter

Novel therapeutic agents for neurological disorders reported in recent patent literature

Novel compounds claimed for use in respiratory disease treatment

CNS-5161, an NMDA receptor antagonist, profiled in vitro and in vivo

Lovastatin to enter the clinic for the treatment of recurrent melanoma / News in Context

Y's Therapeutics advances YSPSL to phase II trials for I/R injury

FDA committee endorses FluMist for children under 5

Vernalis and Servier Research join forces for drug discovery

Oxygent enters phase II for patients undergoing CABG surgery

Genzyme reports encouraging results in Gaucher disease study

Patient enrollment begins in phase III AWARE trial with Generx

Obecure evaluates OBE-101's ability to reduce caloric intake in phase II

BMS's once-daily HIV medicine option approved in Canada

FDA provides feedback for design of Cell Therapeutics' pixantrone phase III trial

MLN-0002 clinical program back on track

Orphan drug designation assigned to Levulan in U.S.

MethylGene selects candidate from antifungal program for clinic

Celladon and Targeted Genetics advance Mydicar into the clinic

Patient enrollment complete for Tovaxin MS trial

MitoPharm's Schisandrin B may hold potential for antiaging concerns

ProtoKinetix's AAGP shows promise in preclinical studies for diabetes

Biolitec's Foscan combined with PDT in SpectraCure prostate cancer clinical trial

Peregrine to study bavituximab for HCV/HIV co-infection

DelSite obtains license to NIH technology for typhoid vaccine

Diractin filed for European approval

Seroquel XR receives FDA approval

Lovenox approved for patients with STEMI

Novel VEGF inhibitor shows therapeutic potential in psoriasis mouse model

Approvable letter for Mircera

Ceftobiprole filed for U.S. approval for cSSSI

SPD-465 receives approvable letter for ADHD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...